Cadosil LD4%+2%+0.025%

Cadosil LD is a fixed-dose combination topical/rectal preparation (vasoprotective agent + local anesthetic + corticosteroid) used for anorectal conditions. Its use is classified below by strength of evidence:

• Established/labeled use: Symptomatic relief of internal and external hemorrhoids (piles) and associated anal conditions (pruritus ani, minor anal fissures, proctitis) - reduces pain, itching, swelling, and vascular fragility/bleeding tendency of the hemorrhoidal tissue. Intended for short-term symptomatic use.
• Adjunct use: May be used as an adjunct to conservative measures (dietary fiber, stool softeners, sitz baths) in the overall management of hemorrhoidal disease; it does not treat the underlying cause and is not a substitute for surgical management when indicated.
• Off-label/physician-directed use: Short-term symptomatic relief after minor anorectal procedures may be used off-label under medical supervision; this is not an FDA/DGDA-labeled indication and should only be used as directed by a physician.

Cadosil LD does not treat the underlying vascular or structural cause of hemorrhoidal disease and should not be used to self-treat rectal bleeding of unknown cause (see Precautions and Warnings).

Each unit (ointment, cream, or suppository, depending on manufacturer presentation) of Calcium Dobesilate + Lidocaine HCl + Dexamethasone Acetate contains Calcium Dobesilate as the vasoprotective/capillary-stabilizing component, Lidocaine HCl as the local anesthetic component, and Dexamethasone Acetate as the corticosteroid (anti-inflammatory) component, combined in a fixed ratio for topical anorectal application. Exact strengths per unit vary by brand/manufacturer; refer to the specific product label for precise composition.

Cadosil LD is a triple-combination topical/rectal product formulated for the local management of hemorrhoids and related anorectal disorders. It brings together three complementary mechanisms in one preparation:

• Calcium Dobesilate - a vasoprotective (capillary-stabilizing) agent that reduces capillary permeability and fragility and modestly inhibits platelet hyperaggregability, helping to reduce local vascular congestion and bleeding tendency.
• Lidocaine HCl - an amide-type local anesthetic that provides rapid, temporary relief of pain and itching at the site of application.
• Dexamethasone Acetate - a potent synthetic corticosteroid that reduces local inflammation, edema, and pruritus.

It is typically presented as an ointment/cream for external application and/or a suppository for internal (intra-rectal) use, and is intended for short-term, physician-directed or product-label-directed symptomatic use.

Anorectal (hemorrhoidal) preparation - combination of a vasoprotective agent, an amide local anesthetic, and a topical corticosteroid

Calcium Dobesilate + Lidocaine HCl + Dexamethasone Acetate combines three distinct pharmacologic actions targeted at the anorectal mucosa and perianal skin:

• Calcium Dobesilate: Reduces abnormal capillary hyperpermeability and fragility, normalizes blood viscosity, and modestly reduces platelet hyperaggregation, which together help reduce local edema, congestion, and the tendency to bleed from fragile hemorrhoidal vessels.
• Lidocaine HCl: Blocks voltage-gated sodium channels in local sensory nerve endings, reversibly preventing the generation and conduction of nerve impulses; this produces rapid, temporary local anesthesia and relief of pain and pruritus.
• Dexamethasone Acetate: Binds intracellular glucocorticoid receptors, down-regulating pro-inflammatory mediators (cytokines, prostaglandins) and reducing local vascular permeability, edema, erythema, and itching associated with anorectal inflammation.

When applied topically/rectally in recommended amounts, systemic absorption of all three components is generally low, but can increase with application to inflamed, excoriated, or extensive mucosal surfaces, or with more frequent/prolonged use than recommended.

Ointment/cream: apply a thin layer externally to the clean, dry perianal area, gently. Suppository: insert one suppository into the rectum, pointed end first, after a bowel movement when possible, and retain in place. Wash hands before and after use. Do not apply to broken or extensively excoriated skin/mucosa beyond the intended treatment area, and avoid contact with the eyes.

Because Cadosil LD is applied topically/rectally and systemic absorption is normally low, clinically significant drug-drug interactions are uncommon with recommended use. Well-recognized interaction risks relate mainly to situations of increased systemic absorption:

• Other local anesthetics or Class I antiarrhythmics (e.g., mexiletine, tocainide): If significant systemic lidocaine absorption occurs (e.g., with overuse or application to extensive/denuded mucosa), concurrent use may have additive effects on cardiac conduction, increasing the risk of arrhythmia.
• Other topical or systemic corticosteroids: Concurrent use of additional corticosteroid-containing products on the same area, or systemic corticosteroids, may increase total corticosteroid exposure and the risk of local or systemic corticosteroid-related effects.
• Other topical anorectal products: Concomitant use of other creams/ointments on the same area may alter local absorption and irritant potential; avoid combining with other anorectal medications unless advised by a physician.

Inform your physician or pharmacist of all other medicines and topical products in use.

Local adverse effects are most common with Cadosil LD; systemic effects are uncommon with recommended short-term use but can occur with overuse or extensive application.

• Common (local): Local burning, stinging, or itching at the application site; local irritation or mild erythema.
• Less common: Local hypersensitivity/allergic contact reactions (rash, contact dermatitis); with prolonged use, local skin/mucosal thinning (atrophy), telangiectasia, or delayed local healing due to the corticosteroid component.
• Rare (usually with excessive/overuse or absorption through broken mucosa): Systemic lidocaine toxicity signs (dizziness, perioral numbness, tinnitus, drowsiness, and rarely seizures or cardiac arrhythmia); systemic corticosteroid effects (e.g., adrenal suppression) with extensive or prolonged use.

Discontinue use and seek medical advice if a rash, worsening irritation, or any signs of systemic toxicity develop.

Pregnancy: Data on the combination product in pregnancy are limited. As with other combination local anesthetic/corticosteroid preparations, Cadosil LD should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; use the smallest effective amount for the shortest necessary duration, and only under medical advice.

Lactation: It is not established whether topically/rectally applied Cadosil LD is excreted in clinically significant amounts in breast milk. Because systemic absorption is normally low with recommended use, use during breastfeeding should still only occur on a physician's advice, avoiding application to the breast area.

Cadosil LD is intended for short-term use only. Key precautions include:

• Duration of use: Use for the shortest period needed (commonly not more than 7 days) unless directed otherwise by a physician; prolonged or repeated corticosteroid exposure increases the risk of local tissue atrophy, thinning, and delayed healing.
• Application limits: Do not exceed the recommended application area, amount, or frequency; excessive use, or use on extensive/denuded mucosa, increases systemic lidocaine absorption and the associated risk of cardiac arrhythmia or CNS toxicity.
• Undiagnosed rectal bleeding: Do not use for active or unexplained anorectal bleeding without prior medical/proctological evaluation, so that more serious underlying pathology (e.g., colorectal neoplasm, inflammatory bowel disease) can be ruled out first.
• Infection: Avoid use if untreated local infection is suspected (see Contraindications); the corticosteroid component may mask or worsen infection.
• Eye contact: Avoid contact with the eyes; rinse thoroughly with water if accidental contact occurs.
• Hepatic impairment: Use with caution and medical supervision, as systemically absorbed lidocaine is metabolized by the liver.

Overdose of Cadosil LD is uncommon with correct topical/rectal use but may occur with significant overapplication, ingestion, or absorption through extensive/broken mucosa. Possible features include systemic lidocaine toxicity (dizziness, tinnitus, perioral or tongue numbness, drowsiness, confusion, and in severe cases seizures, cardiac arrhythmia, or cardiovascular collapse) and, less acutely, corticosteroid-related effects with excessive or prolonged exposure. If overdose or accidental ingestion is suspected, or if any signs of systemic toxicity appear, stop use immediately and seek emergency medical attention or contact a poison control center without delay. Do not attempt specific home treatment beyond stopping the product and seeking care.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze unless the product label states otherwise. Keep out of reach of children.

Children: Safety and efficacy of Cadosil LD in pediatric patients have not been well established; avoid use in infants and young children, whose thinner, more permeable perianal skin/mucosa increases the risk of greater systemic absorption. Use in older children only if specifically directed by a physician.

Elderly: No specific dose adjustment is established for elderly patients; use the standard adult regimen with attention to skin fragility and any coexisting hepatic or cardiac disease.

Hepatic impairment: Use with caution and physician guidance, as systemically absorbed lidocaine is hepatically metabolized and impaired clearance could theoretically increase toxicity risk if significant absorption occurs.

Renal impairment: No well-established dose adjustment is required for this topical/rectal product, since systemic exposure is normally minimal with recommended use.

Generally limited to short-term symptomatic use, commonly not exceeding about 7 days, unless a physician specifically directs a different duration; if symptoms persist beyond this period or worsen, medical reassessment is advised rather than continuing use unsupervised.

Vasoprotective/capillary-stabilizing agent (calcium dobesilate); amide-type local anesthetic (lidocaine); topical corticosteroid/glucocorticoid (dexamethasone acetate)

Calcium Dobesilate + Lidocaine HCl + Dexamethasone Acetate acts through three complementary mechanisms: calcium dobesilate stabilizes capillary walls and reduces abnormal vascular permeability and fragility; lidocaine HCl blocks sodium channels in local sensory nerves to produce temporary anesthesia; and dexamethasone acetate suppresses local inflammatory mediator release via glucocorticoid receptor binding, reducing swelling, redness, and itching.

The safety and efficacy of Cadosil LD in children and adolescents have not been established through controlled studies. Use in pediatric patients is not generally recommended and should occur only under direct physician supervision, given the increased potential for systemic absorption of the local anesthetic and corticosteroid components through thinner perianal skin and mucosa in this age group.